This 1 Thing in Pfizer's Earnings Report May be a Coronavirus Game Changer

This 1 Thing in Pfizer's Earnings Report May be a Coronavirus Game Changer

All eyes were on Pfizer's (NYSE: PFE) coronavirus vaccine sales when it reported second-quarter earnings this week -- and for good reason. The company has fully vaccinated more Americans than its rivals and has established itself as a leader in the worldwide vaccine market, too. Due to more and more orders, Pfizer now expects full-year coronavirus vaccine sales to total $33.5 billion, up from $26 billion.